L. Deannuntis

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2018, Haematologica.

Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.

R. Motzer, B. Rini, B. Escudier, 2015, Clinical genitourinary cancer.

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

H. Rugo, I. C. Tudor, J. Chakrabarti, 2019, The oncologist.